Iradimed Q3 2026 Results: Net Income $6.51M, Up 16.7% YoY
For the nine months ended September 30, 2026, IRADIMED reported revenue of $66.6 million, a 9% increase over the prior year period. Net cash and cash equivalents grew to $63.3 million, while total stockholders' equity increased to $106.5 million from $94.6 million at the end of 2025.
- Key figure
- Net income $6.51M · +16.7% YoY